126 related articles for article (PubMed ID: 24812153)
1. A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats.
Zhang J; Ye L; Wang W; Du G; Yu X; Zhu X; Dong Q; Cen X; Guan X; Fu F; Tian J
Hum Exp Toxicol; 2015 Feb; 34(2):205-23. PubMed ID: 24812153
[TBL] [Abstract][Full Text] [Related]
2. A 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs.
Tian J; Wang W; Ye L; Cen X; Guan X; Zhang J; Yu P; Du G; Liu W; Li Y
Hum Exp Toxicol; 2014 May; 33(5):473-87. PubMed ID: 23925946
[TBL] [Abstract][Full Text] [Related]
3. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process.
An T; Choi J; Kim A; Lee JH; Nam Y; Park J; Sun Bk; Suh H; Kim CJ; Hwang SJ
Int J Pharm; 2016 Apr; 503(1-2):8-15. PubMed ID: 26899975
[TBL] [Abstract][Full Text] [Related]
4. Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats.
Ye L; Guan X; Tian J; Zhang J; Du G; Yu X; Yu P; Cen X; Liu W; Li Y
Food Chem Toxicol; 2013 Jun; 56():81-92. PubMed ID: 23454207
[TBL] [Abstract][Full Text] [Related]
5. Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
Tian J; Du G; Ye L; Yu X; Zhang J; Wang H; Yu P; Fu F; Liu W; Li Y; Cen X; Guan X
Food Chem Toxicol; 2013 Feb; 52():143-52. PubMed ID: 23165154
[TBL] [Abstract][Full Text] [Related]
6. Microsphere delivery of Risperidone as an alternative to combination therapy.
D'Souza S; Faraj J; DeLuca P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
[TBL] [Abstract][Full Text] [Related]
7. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
8. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
Gomeni R; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2013 Oct; 53(10):1010-9. PubMed ID: 23868656
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX
Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594
[TBL] [Abstract][Full Text] [Related]
10. Clinical review of a long-acting, injectable formulation of risperidone.
Knox ED; Stimmel GL
Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
Ereshefsky L; Mascarenas CA
J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
[TBL] [Abstract][Full Text] [Related]
13. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
14. [The new antipsychotic preparation Rispolept (risperidone)].
Iakovlev VA
Voen Med Zh; 1999 Nov; 320(11):43-5. PubMed ID: 10650767
[No Abstract] [Full Text] [Related]
15. Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2015 Jan; 55(1):93-103. PubMed ID: 25043337
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience and management considerations with long-acting risperidone.
Parellada E
Curr Med Res Opin; 2006 Feb; 22(2):241-55. PubMed ID: 16466596
[TBL] [Abstract][Full Text] [Related]
17. Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics.
de Waal EJ; Desmidt M; Korte S; Niehoff M; Chase K; Arrowsmith W; Lampo A
J Appl Toxicol; 2014 Sep; 34(9):974-92. PubMed ID: 24105799
[TBL] [Abstract][Full Text] [Related]
18. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
Duncan EJ; Woolson SL; Hamer RM
Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
[TBL] [Abstract][Full Text] [Related]
19. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients.
Thyssen A; Rusch S; Herben V; Quiroz J; Mannaert E
J Clin Pharmacol; 2010 Sep; 50(9):1011-21. PubMed ID: 20097933
[TBL] [Abstract][Full Text] [Related]
20. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Peng PW; Huang MC; Tsai CJ; Pan CH; Chen CC; Chiu CC
J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
[No Abstract] [Full Text] [Related]
[Next] [New Search]